FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

			of Section So(ii) of the investment Company Act of 1940						
	ss of Reporting Pers		2. Issuer Name and Ticker or Trading Symbol Prelude Therapeutics Inc [PRLD]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner					
(Last)			3. Date of Earliest Transaction (Month/Day/Year) 05/22/2023	Officer (give title Other (specify below) below)					
601 LEXINGTON AVENUE 54TH FLOOR (Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Form filed by More than One Reporting Person					
NEW YORK	NY	10022	Rule 10b5-1(c) Transaction Indication						
(City)	(State)	(Zip)	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

				.,						
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code (I	Transaction Disposed Of (D) (Instr. 3, 4 and Code (Instr. 5)		5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	05/22/2023		Р		869,565 ⁽¹⁾	A	\$5.75	10,119,756	Ι	See footnotes ⁽²⁾ (4)
Common Stock								526,300	Ι	See footnotes ⁽³⁾ (4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

			(0191, 04	,	, .		,	optiono, c			ounno	-)			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transac Code (li 8)		of Deriv Secu Acqu (A) o Dispe of (D	vative virities vired r osed) r. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		ate Amount of			9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

1. Name and Address of Reporting Person*

ORBIMED ADVISORS LLC

54TH FLOOR		(Middle)
	ON AVENUE	
54TH FLOOR Street)		
Street)		
NEW YORK	NY	10022
(City)	(State)	(Zip)
(Last)	(First)	(Middle)
601 LEXINGTO	ON AVENUE, 54	TH FLOOR
601 LEXINGTO	ON AVENUE, 54	TH FLOOR

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

(City)	(State)	(Zip)
1. Name and Address of ORBIMED CA		
(Last) 601 LEXINGTON 54TH FLOOR	(First) AVENUE	(Middle)
(Street) NEW YORK (City)	NY (State)	10022 (Zip)

Explanation of Responses:

1. These shares of the Issuer's common stock were purchased from the Issuer in an underwritten public offering.

2. These securities are held of record by OrbiMed Private Investments VI, LP ("OPI VI"). OrbiMed Capital GP VI LLC ("GP VI") is the general partner of OPI VI and OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VI. By virtue of such relationships, OrbiMed Advisors and GP VI may be deemed to have voting power and investment power over the securities held by OPI VI and, as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the securities held by OPI VI.

3. These securities are held of record by OrbiMed Partners Master Fund Limited ("OPM"). OrbiMed Capital LLC ("OrbiMed Capital") is the investment advisor to OPM. OrbiMed Capital is a relying advisor of OrbiMed Advisors. OrbiMed Advisors and OrbiMed Capital exercise voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPM.

4. Each of OrbiMed Advisors, GP VI, and OrbiMed Capital disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP VI have designated a representative, David Bonita, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any such person or entity is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.

<u>/s/ Carl L. Gordon, Member</u> of OrbiMed Advisors LLC	<u>05/24/2023</u>
<u>/s/ Carl L. Gordon, Member</u> of OrbiMed Capital GP VI LLC	<u>05/24/2023</u>
<u>/s/ Carl L. Gordon, Member</u> <u>of OrbiMed Capital LLC</u>	<u>05/24/2023</u>
** Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.